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INTRODUCTION
Pediatric acute liver failure (PALF) is a rarely encoun-
tered condition characterized by the rapid onset of se-
verely impaired liver function, with or without encepha-
lopathy, and it occurs in children without any previous 
liver disease (1). Age and geographical location affect 
the etiology of PALF. In developing countries, hepati-
tis A is the most significant etiological agent causing 
acute liver failure (ALF) in children (2,3); however, in-
fectious causes are rarely seen in developed countries 
(4). Pediatric ALF Study Group data (4) indicated that 
metabolic diseases were the most common cause of 
ALF in children under 3 years. In children older than 3 
years, acetaminophen intoxication was the main cause. 
However, the cause of ALF still remains undetermined 
in a large proportion of children (5). Some centers with 
and without liver transplantation (LT) facilities in Turkey 
have reported their experience of the etiology of ALF in 
childhood (6-9).
Despite medical therapy, the clinical outcome of PALF is 
poor, and the overall mortality rate is 44–67% (1,4,10,11). 
LT, which is lifesaving, is the only effective treatment 
for suitable patients. With improvement in supportive 
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ABSTRACT
Background/Aims: Our aim was to determine the etiologies, outcomes, and prognostic indicators in children 
with acute liver failure.
Materials and Methods: Ninety-one patients who were followed for pediatric acute liver failure (PALF) over 
a 15-year period were included. Patients who survived with supportive therapy were designated as Group 1, 
while those who died or underwent liver transplantation were designated as Group 2. 
Results: There were 37 (40.6%) patients in Group 1 (spontaneous recovery) and 54 (59.4%) patients in Group 
2. Thirty-two patients (35.2%) underwent liver transplantation. Infectious and indeterminate causes were the 
most common etiologies (33% each). Among the infectious causes, hepatitis A (76%) was the most frequent. 
Hepatic encephalopathy grade 3-4 on admission and during follow-up and high Pediatric Risk of Mortality 
(PRISM) and Pediatric End-Stage Liver Disease (PELD) scores within the first 24 h were related with a poor prog-
nosis. Group 2 had a more prolonged prothrombin time, higher international normalized ratio, more prolonged 
activated partial thromboplastin time (aPTT), and higher levels of total and direct bilirubin, ammonia, and lac-
tate (for all, p<0.01).
Conclusion: Infectious and indeterminate cases constituted the most common etiology of PALF, and the eti-
ology was related to the prognosis in our series. Although high PELD and PRISM scores were related to poor 
prognoses, no sharp thresholds for individual laboratory tests could be elucidated. Liver transplantation was the 
only curative treatment for patients with poor prognoses and resulted in high survival rates (1-, 5-, and 10-year 
survival rates of 81.3%, 81.3%, and 75%, respectively) in our study.
Keywords: Acute liver failure, pediatric, prognostic factors
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therapy and LT, overall survival rates have increased to 62–83% 
(4,10,11). Diverse combinations of age, etiologies of ALF, onset 
and peak grade of hepatic encephalopathy (HE), biochemical 
tests [prothrombin time (PT), the international normalized ra-
tio (INR), bilirubin, ammonia, and lactate], Pediatric End-Stage 
Liver Disease (PELD) score, several chemokines, cytokines, and 
reactive nitrogen oxide species have been evaluated to assess 
the prognosis of PALF (2,12,13). Applying King’s College Hospi-
tal Criteria to children with PALF did not predict death, and the 
reported positive predictive value was only 33% (14).
The PELD score predicts a high mortality risk in children with 
chronic liver disease listed for LT. A PELD score in ALF is re-
ported to be useful for establishing the optimal timing for LT 
evaluation (15). The Pediatric Risk of Mortality (PRISM) score 
was developed to assess the severity of illness-related mortal-
ity in pediatric intensive care units, irrespective of the diagno-
sis. The PRISM score includes 14 well-defined routine clinical 
and laboratory variables. This scoring system has been evalu-
ated and validated in critically ill patients and has been found 
to be reliable in predicting mortality. The PRISM score has been 
validated under various conditions, including ALF (16). The aim 
of this study was to determine the etiologies, outcomes, and 
prognostic indicators, including PELD and PRISM scores, in pa-
tients with ALF in our center and the pediatric LT unit.
MATERIALS AND METHODS
We evaluated the medical records of 91 pediatric patients with 
ALF who were accepted to our Pediatric Gastroenterology Unit 
between January 2000 and October 2015. The study was ap-
proved by the Institutional Review Board (KA 09/84). Informed 
consent was obtained from the parent or legal guardian of 
each participant.
We used the Pediatric ALF Study Group criteria for defining 
ALF: 1) absence of a previously known history of chronic liver 
disease, 2) biochemical evidence of acute liver injury, and 3) 
hepatic-based coagulopathy defined as PT≥15 s or INR≥1.5 
not corrected by vitamin K in the presence of clinical HE or 
PT≥20 s or INR≥2 regardless of the presence or absence of 
clinical HE (4).
We graded HE using the following standard criteria: Grade 1: 
alert, mood changes, slow mentation, inconsolable crying, dis-
turbed sleep–awake cycle; Grade 2: lethargy, confusion, inap-
propriate behavior; Grade 3: somnolence, stupor; and Grade 
4: comatose, increased or flaccid muscle tone (17). We did not 
assess the HE grade in children under 1 year.
We analyzed the medical records and data, including the clini-
cal and laboratory parameters, namely, age; gender; PALF eti-
ology; transaminases, gamma-glutamyl transferase, alkaline 
phosphatase, ammonia, albumin, lactate, and bilirubin levels; 
aPTT; PT; INR; fibrinogen; HE grade on admission; and the high-
est grade of HE during follow-up.
We calculated the PRISM scores using 14 measured physi-
ologic variables for each patient: systolic and diastolic arterial 
pressures; heart and respiratory rates; PaO2/FiO2 ratio; PaCO2; 
PT; total bilirubin; calcium, potassium, blood glucose, and se-
rum bicarbonate levels; pupil response; and Glasgow coma 
scale (16). Using admission laboratory data, we calculated the 
PELD scores with an online calculator www.unos.org/resource/
meldpeldcalculator (18).
We investigated infectious, metabolic, toxic, and autoimmune 
diseases in order to identify the cause of PALF. The laboratory 
tests included complete blood count; blood, urine, and stool 
cultures; Widal test for typhoid fever; and viral hepatitis sero-
logical tests [including HAV, HBV, HCV, HEV, EBV, CMV, HSV type 
1 and 2, and parvovirus B19]. Wilson’s disease was screened 
with 24-h urinary copper excretion and ceruloplasmin. Auto-
antibodies (anti-smooth muscle, anti-nuclear, and liver-kidney 
microsomal antibody) and metabolic screening, including tan-
dem mass spectrometry, urine organic acid analysis and serum 
lactate, pyruvate, and ferritin levels, were studied. In cases where 
no positive viral markers, no history of toxin or drug exposure, 
and no metabolic cause were detected, the etiology of PALF 
was classified as indeterminate. All patients received medical 
supportive therapy for PALF (electrolyte and glucose replace-
ment, N-acetylcysteine, oral and intravenous antibiotics, laxa-
tives, and H2-receptor blocker) and specific treatment for any 
identifiable causes and complications. Plasma exchange was 
performed for 68% of the patients. The indication for LT was 
based on progressive coagulopathy or progressive HE, despite 
supportive therapy including plasma exchange (19).
We divided the patients into two groups depending on the 
outcome in order to search for the predictors of prognosis: 
Group 1 included patients who had spontaneous recovery 
with supportive therapy; Group 2 included patients who re-
ceived LT or died without LT. We assessed certain clinical and 
laboratory parameters between these groups: age, gender, eti-
ology of ALF, HE grade on admission, and the highest grade of 
HE. On admission, the PRISM and PELD scores; bilirubin, lactate, 
and NH3 levels; aPTT; PT; and INR were recorded.
Statistical analysis
Statistical analyses were performed using the SPSS for Win-
dows version 17.0 (SPSS Inc.; Chicago, IL, USA). The mean and 
standard deviation were calculated for numeric variables, while 
counts and percentages were used for categorical variables. 
Continuous variables were compared using Student’s t-test or 
the nonparametric Mann–Whitney rank sum test for unpaired 
data. Categorical variables were compared by the Chi-squared 
or Fisher’s exact test. A p value of less than 0.05 was consid-
ered statistically significant. Multivariate analysis using logistic 
regression was performed to identify associations between 
the variables and risk factors for LT and death. An area under 
the ROC curve (AUC) of >0.8 indicates an excellent diagnostic 
accuracy, while a model with an AUC>0.7 may be considered 
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clinically useful. Variables calculated to describe the prognostic 
value in ALF included sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV) for the labora-
tory tests.
RESULTS
Demographic characteristics
We evaluated 91 children with ALF (46 males, 45 females) over 
a 15-year period of time. At the time of presentation, the me-
dian age of the patients was 67.9 months (range: 11 days to 
17 years). The age distribution was as follows: <1 month, 1.1% 
(n=1); 1 to 12 months, 8.8% (n=8); 1 to 5 years, 39.6% (n=36); 
>5 years, 50.5% (n=46). The parents of 24 (26.3%) patients were 
consanguineous.
Etiology
The etiologies of PALF, including 33% (n=30) infectious, 33% 
(n=30) indeterminate, 15.4% (n=14) toxic, 12.1% (n=11) meta-
bolic, 3.3% (n=3) hemophagocytic syndrome, 2.2% (n=2) car-
diac causes, and 1.1% (n=1) autoimmune causes, are given in 
Figure 1. We determined different etiologies for ALF in the dif-
ferent age groups (Table 1).
Clinical presentation, laboratory analysis, and outcome
The most common clinical findings during presentation were 
jaundice (n=84, 92.3%), hepatomegaly (n=64, 70.3%), spleno-
megaly (n=32, 35.2%), ascites (n=18, 19.8%), edema (n=12, 
13.1%), and fever (n=12, 13.1%). The HE grade could not be as-
sessed in 9 (9.8%) patients due to young age, while HE was not 
seen in 13 (14.3%) patients on admission and during follow-up. 
During follow-up, mild HE (grade 1–2) was present in 24.2% 
(22/91) patients, of whom 68.1% spontaneously survived, and 
31.8% received LT or died. Moderate to severe HE (grade 3–4) 
was present in 51.6% (47/91) patients, of whom 14.8% sponta-
neously survived, and 85.1% received LT or died. The HE grades 
on admission and during follow-up are listed in Table 2.
The rate of spontaneous recovery with supportive therapy was 
40.6% (n=37), while 24.2% (n=22) died, and 35.2% (n=32) re-
ceived LT. Fifteen patients who died without LT were consid-
ered and listed for LT; however, the patients died while await-
ing suitable donors due to multiorgan failure and/or sepsis. 
LT was contraindicated in seven children due to irreversible 
neurologic damage secondary to very late referral. Thirty-two 
patients received LT (Figure 2); however, seven (22%) patients 
died following LT. The mean duration of follow-up after LT was 
3515±359 days (range: 434–4610 days). One-, 5-, and 10-year 
survival rates of liver transplanted patients were 81.3%, 81.3%, 
and 75% respectively (Figure 3).
Concomitant infections and conditions
Patients with positive blood or urine cultures or with pulmo-
nary infiltration on admission or during follow-up were also 
investigated. The microorganisms that were isolated from the 
blood cultures of patients who spontaneously survived were 
coagulase negative Staphylococcus (CONS) in three patients and 
Staphylococcus aureus in two. Escherichia coli was isolated from 
urine culture in one patient and three patients had pulmonary 
infiltration. As a result, the frequency of infection was deter-
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Figure 1. Etiology of acute liver failure (HPS: hemophagocytic lymphohis-
tiocytosis)
   Infancy Early  
  Neonatal 1–12 childhood Childhood 
  <28 days months 1–5 years >5 years 
  (n=1)  (n=8)  (n=36)  (n=46)
Infectious causes, total (n=30)
 Hepatitis A (n=23) - - 12 11
 EBV (n=3)  - - 2 1
 Adenovirus (n=1) -  - 1 -
 Hepatitis B (n=1) - - - 1
 Salmonellosis (n=1) - - - 1
 Klebsiella sepsis (n=1) 1 - - -
Indeterminate, total (n=30) - 6 11 13
Metabolic causes, total (n=11)    
 Fulminant Wilson’s disease (n=7) - - - 7
 Tyrosinemia (n=1) - 1 - -
 Fatty acid oxidation defect (n=2) - - 2 -
 N. hemochromatosis (n=1) - 1 - -
Toxic causes, total (n=14)    
 Mushroom poisoning (n=6) - - 3 3
 Drugs (n=6) - - 1 5
 Firework poisoning (n=2) - - 1 1
Autoimmune hepatitis (n=1) - - - 1
Other causes, total (n=5)    
 Hemophagocytic syndrome (n=3) - - 2 1
 Myocarditis/cardiomyopathy (n=2) - - 1 1
ALF: acute liver failure; EBV: Epstein–Barr virus
Table 1. Etiologies of ALF according to age
mined as 16.2% in Group 1. The microorganisms that were iso-
lated from the blood cultures of patients in Group 2 were CONS 
in three patients, Klebsiella pneumoniae in two patients, and 
Streptococcus mitis in one patient. Seven patients had positive 
urine culture; Escherichia coli was isolated in four samples, Kleb-
siella pneumoniae was isolated in two samples, and Klebsiella 
oxytoca was isolated in one sample. As a result, the frequency 
of infection was determined as 31.25% in Group 2.
Four patients (7.4%) in Group 2 had acute renal failure compli-
cating PALF during the course of their illnesses. Four patients 
who were diagnosed with fulminant Wilson’s disease had se-
vere Coombs negative hemolytic anemia. Two patients (one 
with EBV hepatitis and one with indeterminate cause) had 
aplastic anemia. One patient recovered and the other one 
underwent bone marrow transplantation. Generalized convul-
sions were seen in seven patients and one patient had acute 
pancreatitis.
Prognostic indicators
The age of patients who received LT or died and who survived 
with supportive therapy was similar (p=0.078). Children with 
PALF from toxic causes (11 of 14 patients, 78.5%) and hepatitis A 
(12 of 23 patients, 52.1%) had higher survival rates with support-
ive therapy; however, patients with fulminant Wilson’s disease 
(none of 7 patients) and those with an indeterminate etiology (6 
of 30 patients, 20%) had lower survival rates without LT (Table 2).
Patients with grade 1 and 2 HE on admission and follow-up 
were more likely to recover without LT than those with grade 3 
and 4 HE (both, p<0.001). The mean values for the PRISM and 
PELD scores on admission were significantly higher in Group 
2 than in Group 1 (17.53±9.57 vs 10.78±6.78, p<0.001 and 
33.59±10.56 vs 21.07±9.09, p<0.001, respectively). The mean 
values for serum total bilirubin, direct bilirubin, ammonia, lac-
tate, aPTT, PT, and INR were significantly different between 
groups 1 and 2 (Table 3).
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  Group 1 (n=37) Group 2 (n=54)
  Spontaneous Received LT  
  recovery or died p
Sex (male)a  16 (43.2%) 30 (55.5%) 0.347
Age, monthsb  60.3±49.8 79.1±49.4 0.078
HE (on admission)a   <0.001
 None 11 (29.7%) 2 (3.7%) 
 Grade 1+2 19 (51.4%) 23 (42.6%) 
 Grade 3+4 3 (8.1%) 24 (44.4%)
 Not assessed 4 (10.8%) 5 (9.3%)
HE (peak level)a   <0.001
 None 11 (29.7%)   2 (3.7%) 
 Grade 1+2 15 (40.5%)  7 (13%) 
 Grade 3+4 7 (18.9%) 40 (70.1%)
 Not assessed 4 (10.8%) 5 (9.3%) 
PRISM scorec 10.78±6.78 17.5±9.57 <0.001
PELD scorec 21.07±9.09 33.59±10.56 <0.001
Total bilirubin (mg/dL)c 12.96±12.13 26.03±13.91 <0.001
Direct bilirubin (mg/dL)c 9.16±8.71 16.85±10.41 <0.001
Ammonia (µmol/L) 103.61±99.11 118.05±96.58 <0.001
Lactate (mmol/L) 2.85±2.04 5.19±3.90 <0.001
aPTT (s)c 48.21±22.74 58.23±29.08 0.006
PT (s)c  32.30±12.76 46.47±23.86 <0.001
INRc 3.26±1.67 5.05±3.30 <0.001
aValues are given as percentage.
bValues are given as median and range.
cValues are given as mean±standard deviation.
LT: liver transplantation; ALF: acute liver failure; HE: hepatic encephalopathy; PRISM: 
Pediatric Risk of Mortality; PELD: Pediatric End-Stage Liver Disease; aPTT: activated partial 
thromboplastin time; PT: prothrombin time; INR: international normalized ratio
Table 2. Demographic, clinical, and laboratory findings of patients with ALF
Figure 3. Postoperative cumulative survival rate of patients with ALF who 
underwent liver transplantation at 1, 5, and 10 years (81.3%, 81.3%, and 75%)
Figure 2. Study assignment and outcomes of patients with ALF
Hepatic encephalopathy on admission to the hospital and the 
highest grade of HE during follow-up, the PRISM and PELD scores 
on admission, bilirubin levels, ammonia, lactate, aPTT, PT, and 
INR were assessed using logistic regression analysis to evaluate 
independent predictors of the outcome. The following factors 
remained independently associated with poor prognosis: devel-
oping grade 3–4 HE (OR; 12.86, 95% CI, 1.29–128.34), higher total 
bilirubin levels (OR; 1.17, 95% CI, 1.05–1.18), and prolonged PT (OR; 
1.05, %95 CI, 1–1.18). A cutoff of 32.1 s in PT levels using the receiv-
er operating characteristic curves showed 70.3% specificity and 
70.4% sensitivity for a poor outcome (PPV 77.6% and NPV 61%; 
AUC 0.728); while a cutoff of 8.4 mg/dL total bilirubin levels using 
the receiver operating characteristic curves showed 56.8% speci-
ficity and 92.6% sensitivity for a poor outcome (PPV 75.8% and 
NPV 84%; AUC 0.779). Although the PELD and PRISM scores were 
significantly different between groups, we found them ineffective 
in predicting a poor prognosis in logistic regression analysis.
DISCUSSION
The aim of this study was to determine the etiological char-
acteristics and prognostic outcomes of patients who were 
treated for PALF during January 2000 to October 2015 in our 
hospital. To date, pediatric ALF has been evaluated in certain 
reports from Turkey (6-8). In our series, infectious (33%) and 
indeterminate etiologies (33%) were the most common un-
derlying causes, while among the infectious causes, hepatitis 
A (76.6%) was the most frequent one. Viral hepatitis accounted 
for less than 10% of cases of ALF (10,20) in developed countries. 
However, a previous Turkish study conducted between 1997 
and 2003 showed that an infectious etiology (35%) (hepatitis 
A constitutes 71% of infectious causes) was the most common 
cause of ALF (6). In a study from Argentina (2) of 210 children 
with ALF, the authors showed that the main cause of ALF was 
HAV infection (61%). In the past few years, a study from the 
pediatric LT center in France (21) showed infectious etiology, 
particularly hepatitis A, was the main cause of ALF (22%) and 
accounted for 10% of LT performed at this center. Sanitation, 
high socioeconomic standards, and vaccination play an im-
portant role in the protection against HAV infection. A national 
vaccination program for HAV was initiated in October 2012 in 
Turkey, and we believe that achieving a high percentage of 
vaccination will reduce the incidence of HAV infection and ALF 
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  Total Supportive therapy Survival with transplantation Died after transplantation Died before transplantation 
  (n=91)  (n=37)  (n =26)    (n=6)  (n=22)
Infectious causes (n=30)     
 Hepatitis A   23 12 6 2 3
 EBV   3 1 - - 2
 Adenovirus 1 - - 1 -
 Hepatitis B 1 - - 1 -
 Salmonellosis 1 1 - - -
 Klebsiella sepsis 1 - - - 1
Indeterminate (n=30) 30 6 11 2 11
Metabolic causes (n=11)     
 Fulminant Wilson’s disease 7 - 6 - 1
 Tyrosinemia 1 1 - - -
 Fatty acid oxidation defect 2 2 - - -
 N. hemochromatosis 1 - - - 1
Toxic causes (n=14)     
 Mushroom poisoning 6 5 1 - -
 Drugs 6 4 1 - 1
 Firework poisoning 2 2 - - -
Autoimmune hepatitis (n=1) - 1 - -
Other causes (n=5)  - - - 2
 Hemophagocytic syndrome 3 1 1 - 1
 Myocarditis 1 - - - 1
 Dilated cardiomyopathy 1 1 - - -
ALF: acute liver failure; EBV: Epstein–Barr virus
Table 3. Survival according to the etiologies of ALF
secondary to hepatitis A. HBV infection has also been reported 
to be an important cause of ALF, with a prevalence of 8.8% in 
southern Asia (22). Kayaalp et al. (9) reported that hepatitis B 
was the most common etiology (34.6%) of ALF in adults in Tur-
key, which was much more frequent than the etiology of ALF 
in children (2.3%). Previous studies from Turkey (6,7) reported 
pediatric ALF cases caused by HBV; however, in our study we 
identified only one case (1.1%) of hepatitis B. The low rate of 
hepatitis B in children may possibly be attributed to the suc-
cessful national HBV vaccination program, which has been in 
effect since 1998. In most countries in northern Europe, and in 
North and South America (2,4,10,23,24), indeterminate causes 
predominate in ALF in childhood, whereas acetaminophen 
toxicity was the most common identifiable cause of ALF in 
older children. In our study, etiology remained indeterminate 
in 33% of patients.
Metabolic causes for PALF have higher rates in infants than in 
older children (4,25). The series of Lee et al. (10) showed that 
neonatal hemochromatosis, while that of Durand et al. (25) re-
ported that mitochondrial respiratory chain disorders, were the 
most frequent causes in neonates. Our study included only one 
neonatal ALF case diagnosed with Klebsiella sepsis and two 
cases secondary to neonatal hemochromatosis and tyrosin-
emia in early infancy. A study from Turkey (7) found that meta-
bolic causes were the most common etiology in children with 
ALF; likewise, fulminant Wilson’s disease was the most com-
mon metabolic cause in children aged 5–12 years. Similarly, in 
our series, fulminant Wilson’s disease was the most common 
metabolic cause of ALF in the late childhood period. However, 
other metabolic diseases were rarely recorded in our ALF cases. 
This finding could be secondary to the low percentage of in-
fants in our series. The low referral rate of young infants to our 
hospital could be explained with the referral of these groups of 
patients to other centers that have a department of pediatric 
metabolic diseases.
The Pediatric ALF Study Group showed that the toxic causes of 
ALF, particularly acute acetaminophen toxicity, were the most 
common identifiable causes of ALF in children older than 3 
years (4). Drug-related ALF cases were seen in six patients in 
our study, and atomoxetine, acetaminophen, anti-tuberculous 
drugs, and isoflurane were suspected as the causative agents 
of ALF (26). Mushroom poisoning was the most common toxic 
cause of ALF in our study. A systematic review reported that 
mushroom intoxication was the most frequent factor of toxic 
liver failure for both adults and children (13%) in Turkey (9). 
This can lead to ALF with high mortality, which is likely due 
to late presentation (27). The molecular adsorbent recirculat-
ing system has been used to enable native liver recovery and 
as a bridging treatment to LT (28). In the present study, five of 
the six patients with mushroom poisoning recovered with ear-
ly supportive therapy that included charcoal hemadsorption 
and plasma exchange, while only one patient received LT.  In-
creased community and medical awareness are important to 
reduce the frequency, morbidity, and mortality of mushroom 
and firework (yellow phosphorus) poisoning (29).
The prognosis is influenced by several factors, including age, 
etiology, and laboratory findings in ALF. Rajanayagam et al. (30) 
observed ages below 3 months to be associated with poor 
prognoses. In our series, age was not related to the poor prog-
nosis. The etiology was the other most important prognostic 
indicator in the literature (4,30). In our study, the spontaneous 
survival rate was higher in ALF, secondary to hepatitis A and 
toxic causes. However, fulminant Wilson’s disease and indeter-
minate cases had lower survival rates without LT.
The duration of illness before the onset of HE and the degree 
of HE at the time of presentation have been extensively investi-
gated in numerous studies (2,25,31). Patients with the rapid de-
velopment of HE after the onset of clinical disease were found to 
more likely survive without LT. A study from Argentina (2) showed 
that one of the most significant indicators of a poor prognosis 
was grade 3 to 4 HE. Our study revealed that patients who sur-
vived with supportive therapy had a less severe HE grade (1 or 
2) on admission and follow-up. Some studies have evaluated the 
prognostic accuracy of the PELD and PRISM scores upon hos-
pital admission (15,16,30). Sanchez and D’Agostino (15) showed 
that PELD scores on admission were significantly higher among 
non-survivors (39.8±9.5) and LT recipient (39±7.1) than among 
those who survived without LT (31.3±3) (p<0.001), and they 
emphasized that PELD scores on admission could significantly 
determine a poor outcome. In our study, the presence of higher 
values of PELD scores on admission was related to a poor prog-
nosis. However, Rajanayagam et al. (30) reported that instead of 
a single PELD score on admission, serial PELD scores and peak 
values during follow-up were superior for an evaluation of the 
prognosis. However, we did not examine serial PELD scores in 
our study. The reason for this was because our supportive thera-
pies, including plasmapheresis, interacted with the PELD score 
variables. The PRISM score was investigated in patients with ALF 
(16,32). Tissières et al. (32) observed that the PRISM score is an ac-
curate means of severity assessment in pediatric ALF; however, 
the assessment of mortality by the PRISM score has a low pre-
dictive value. We also found that PRISM scores were significantly 
higher in those who received LT or with those who died than in 
those who survived with supportive therapy. The findings of this 
study suggest that the PELD and PRISM scores obtained upon 
admission may be helpful to ascertain the prognosis. Sanchez 
and D’Agostino (33) reported that a cutoff of 33 in the PELD 
score showed 81% specificity and 86% sensitivity for a poor out-
come. Although the PELD and PRISM scores were significantly 
different between the groups, we could not determine a cutoff 
to indicate a poor prognosis in our study.
Several laboratory parameters, such as PT(2), serum bilirubin 
(2,33), serum phosphate (8), lactate (35), ammonia (36), albu-
min (37), and factor V and factor VII38, were assessed to identify 
a poor prognosis. In the present study, patients who died or 
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received LT tended to have higher serum total bilirubin, direct 
bilirubin, ammonia and lactate levels, aPTT, PT, and INR. After 
using logistic regression analysis, advanced HE, serum total 
bilirubin, and higher PT indicated death and the need for LT. 
PT≥32.1 s and a total bilirubin level≥8.4 mg/dL were shown 
to be risk factors for a poor outcome. The cutoff for bilirubin 
is different than that reported previously in another center 
from Turkey, where Bariş et al. (7) reported that a total bilirubin 
level of >5.35 mg/dL was associated with an increased risk of 
mortality. This difference between bilirubin levels could be at-
tributed to the differences in the etiologies of PALF between 
the centers, whereby infectious and indeterminate etiologies 
predominated in our study, while metabolic diseases were the 
most common causes of PALF in the other center.
Spontaneous survival without LT was 40.6% in the patients in-
cluded in our study, which is higher than that in previous re-
ports (28%, 32.4%, 33%, respectively) (2,7,10). Early referral of 
patients with PALF and improved intensive care supportive 
treatment lead to an increased spontaneous survival rate (14). 
LT significantly improves the prognosis of ALF (39). Before, the 
post-transplant outcome of children with ALF was considered 
to be poor when compared with patients with chronic liver 
disease. However, recently, improved outcomes have been re-
ported, with cumulative survival rates of the grafts at 1 and 5 
years of 81.9% and 79.2%, respectively (40). In our series, the 1-, 
5-, and 10-year survival rates of patients with PALF who under-
went LT were 81.3%, 81.3%, and 75%, respectively, which are 
comparable with those in other centers.
In conclusion, PALF is a life-threatening condition. For this rea-
son, referring the patient to the LT center on time, estimating 
the likelihood of spontaneous survival, and identifying patients 
who cannot recover without LT are necessary.
Although prognostic factors that predict mortality and the 
need for early LT are vigorously required in children, they have 
not been determined yet. However, the presence of the follow-
ing factors was found to predict a poor prognosis: a higher HE 
grade, a higher bilirubin level, and severe coagulopathy. Chil-
dren with PALF should be closely monitored with all relevant 
clinical and laboratory parameters together. LT can achieve 
considerable long-term success for patients who would other-
wise die secondary to liver failure and its complications.
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